PURPOSE: Feverfew is a botanical product that contains parthenolide. Parthenolide has in vitro and in vivo anti-tumor and anti-angiogenic activity. Feverfew has been used extensively without any formal pharmacokinetic analysis. A Phase I trial was conducted to evaluate the pharmacokinetics and toxicity of parthenolide given as a component of "feverfew." PATIENTS AND METHODS: Feverfew (Tanacet trade mark ) was administered as a daily oral tablet in a 28-day cycle. A starting dose of 1 mg per day was explored with subsequent dose escalations to 2, 3, and 4 mg. Assessment of plasma pharmacokinetics was performed on patients accrued to the trial. Solid phase extraction and mass spectroscopy were used to evaluate parthenolide plasma concentrations. The limit of detection for parthenolide in plasma was 0.5 ng/ml. Patients were evaluated for response after every two cycles. RESULTS: Feverfew given on this schedule had no significant toxicity, and the maximum tolerated dose was not reached. When parthenolide was administered at doses up to 4 mg as a daily oral capsule in the feverfew preparation, there was not detectable concentration in the plasma. Because of this, parthenolide pharmacokinetics were not able to be completed. CONCLUSION: Feverfew, with up to 4 mg of parthenolide, given daily as an oral tablet is well tolerated without dose-limiting toxicity, but does not provide detectable plasma concentrations. Purification of parthenolide for administration of higher doses will be needed.
PURPOSE:Feverfew is a botanical product that contains parthenolide. Parthenolide has in vitro and in vivo anti-tumor and anti-angiogenic activity. Feverfew has been used extensively without any formal pharmacokinetic analysis. A Phase I trial was conducted to evaluate the pharmacokinetics and toxicity of parthenolide given as a component of "feverfew." PATIENTS AND METHODS: Feverfew (Tanacet trade mark ) was administered as a daily oral tablet in a 28-day cycle. A starting dose of 1 mg per day was explored with subsequent dose escalations to 2, 3, and 4 mg. Assessment of plasma pharmacokinetics was performed on patients accrued to the trial. Solid phase extraction and mass spectroscopy were used to evaluate parthenolide plasma concentrations. The limit of detection for parthenolide in plasma was 0.5 ng/ml. Patients were evaluated for response after every two cycles. RESULTS:Feverfew given on this schedule had no significant toxicity, and the maximum tolerated dose was not reached. When parthenolide was administered at doses up to 4 mg as a daily oral capsule in the feverfew preparation, there was not detectable concentration in the plasma. Because of this, parthenolide pharmacokinetics were not able to be completed. CONCLUSION:Feverfew, with up to 4 mg of parthenolide, given daily as an oral tablet is well tolerated without dose-limiting toxicity, but does not provide detectable plasma concentrations. Purification of parthenolide for administration of higher doses will be needed.
Authors: Milos Sovak; Allen L Seligson; Martin Konas; Marian Hajduch; Marek Dolezal; Miroslav Machala; Robert Nagourney Journal: J Natl Cancer Inst Date: 2002-09-04 Impact factor: 13.506
Authors: D Bissett; A Setanoians; J Cassidy; M A Graham; G A Chadwick; P Wilson; V Auzannet; N Le Bail; S B Kaye; D J Kerr Journal: Cancer Res Date: 1993-02-01 Impact factor: 12.701
Authors: Zaineb A F Albayati; Venumadhav Janganati; Zheng Chen; Jessica Ponder; Philip J Breen; Craig T Jordan; Peter A Crooks Journal: Bioorg Med Chem Date: 2016-12-26 Impact factor: 3.641
Authors: Yulin Ren; Esperanza J Carcache de Blanco; James R Fuchs; Djaja D Soejarto; Joanna E Burdette; Steven M Swanson; A Douglas Kinghorn Journal: J Nat Prod Date: 2019-03-04 Impact factor: 4.050
Authors: Karin Jöhrer; Marlene Obkircher; Daniel Neureiter; Johanna Parteli; Claudia Zelle-Rieser; Eva Maizner; Johann Kern; Martin Hermann; Frank Hamacher; Olaf Merkel; Nathalie Wacht; Christian Zidorn; Marcel Scheideler; Richard Greil Journal: J Mol Med (Berl) Date: 2011-12-29 Impact factor: 4.599